Safety and Efficacy of Pegylated Liposomal Doxorubicin in HIV-associated Kaposi’s Sarcoma

Biologics: Targets and Therapy - New Zealand
doi 10.2147/btt.s3915
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Histological Evidence for the Cardiac Safety of High-Dose Pegylated Liposomal Doxorubicin in a Patient With HIV-associated Kaposi Sarcoma: A Case Report and Literature Review

BMC Infectious Diseases
Infectious Diseases
2019English

Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy

OnCOReview
Oncology
2017English

Massive Vulval Kaposi’s Sarcoma in Pregnancy: Case Report

International Medical Case Reports Journal
Medicine
2016English

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

PLoS ONE
Multidisciplinary
2013English

Kaposi Sarcoma in HIV Infected Patients

Acta Medica Marisiensis
2016English

Pulmonary Kaposi's Sarcoma - Initial Presentation of HIV Infection 

Folia Medica
Medicine
2019English

A Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Patients With Advanced Kaposi Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy